Patents Examined by Lianko G Garyu
-
Patent number: 11971413Abstract: The embodiments disclosed herein provide a peptoid, which is a compound of Formula I or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof. N—R4, N—R3, N—R2, and N—R1 in Formula I are respectively. The peptoid has a strong binding ability with an EpCAM protein. It can be used as molecular probes for diseases associated with an EpCAM protein, to achieve targeted therapy, in vivo imaging diagnosis and prognosis monitoring of the diseases associated with the EpCAM protein at low cost, high accuracy and high efficiency.Type: GrantFiled: October 10, 2019Date of Patent: April 30, 2024Assignees: BEIJING BOE TECHNOLOGY DEVELOPMENT CO., LTD., BOE TECHNOLOGY GROUP CO., LTD.Inventor: Zijian Zhao
-
Patent number: 11963534Abstract: An application of fengycin family lipopeptides in pest control is provided, and Fengycin family lipopeptides are used for pest control, with especially strong killing effects on Homoptera and Coleoptera pests. A method is provided for treating seeds with fengycin to protect seeds and plant organs formed later from pests, so as to protect seeds from pests by coating the fengycin family lipopeptides on the surface of seeds.Type: GrantFiled: November 18, 2022Date of Patent: April 23, 2024Assignee: INSTITUTE OF BIOLOGY, HEBEI ACADEMY OF SCIENCESInventors: Hongwei Liu, Caimiao Yao, Yongfeng Liu, Liping Zhang, Yana Wang, Wenya Zhao
-
Patent number: 11957761Abstract: Compounds of formula (1): and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are ?4?7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.Type: GrantFiled: December 20, 2022Date of Patent: April 16, 2024Assignee: Zealand Pharma A/SInventor: Stefan Schunk
-
Patent number: 11957731Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: September 2, 2022Date of Patent: April 16, 2024Assignee: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11951204Abstract: The present disclosure relates to a novel cell-penetrating multifunctional peptide, a composition including the same.Type: GrantFiled: September 27, 2022Date of Patent: April 9, 2024Assignee: S-SKIN. CO., LTD.Inventors: Byung-Il Kim, Jeong Hee Im, Jeong Gun Lee
-
Patent number: 11919929Abstract: The invention provides for the expression and purification of a recombinant form of FABP (Fh15) exhibiting a similar suppressive effect on TLR-stimulation and inflammatory cytokine expression from macrophages than those previously demonstrated for the native molecule. Fh15 suppresses the expression of IL-1? and TNF? in murine macrophages and THP1 Blue CD14 cells. Additionally, Fh15 suppress the LPS-induced TLR4 stimulation. This effect was not impaired by a thermal denaturing process or blocked by the presence of anti-Fh12 antibodies. Fh15 also suppressed the stimulation of various TLRs in response to whole bacteria extracts so that Fh15 could be an excellent alternative for an anti-inflammatory drug in preclinical studies in the near future.Type: GrantFiled: February 20, 2019Date of Patent: March 5, 2024Assignee: UNIVERSITY OF PUERTO RICOInventors: Ana M. Espino, Marcos J. Ramos-Benitez
-
Patent number: 11918621Abstract: Provided herein are methods of mitigating and/or preventing side effects from chemotherapy and/or radiotherapy in a subject by administering a therapeutically effective amount of a toll-like receptor 2/6 (TLR 2/6) ligand, including fibroblast-stimulating lipopeptide 1 (FSL-1). Methods of treating and/or preventing gastrointestinal disorders are also disclosed. Additionally, methods of increasing granulocyte colony-stimulating factor (G-CSF) production in a subject undergoing a medical treatment, including administering FSL-1 compositions, are provided.Type: GrantFiled: November 19, 2018Date of Patent: March 5, 2024Assignee: The University of North Carolina at Chapel HillInventors: Jenny P.-Y. Ting, Willie June Brickey, Hao Guo, Cathryn Julia Robbins
-
Patent number: 11865157Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).Type: GrantFiled: January 20, 2023Date of Patent: January 9, 2024Assignees: University of Houston System, The Board of Regents of the University of Texas SystemInventors: Damith Gomika Udugamasooriya, Aaron Raymond, John Minna
-
Patent number: 11858973Abstract: The present invention relates to granulysin, method of obtaining same, and uses, specifically to the granulysin polypeptide for the use thereof as a medicinal product via the systemic route and to a chimeric molecule comprising a recombinant antibody targeting a tumor antigen and the granulysin polypeptide.Type: GrantFiled: July 24, 2019Date of Patent: January 2, 2024Assignees: UNIVERSIDAD DE ZARAGOZA, FUNDACIÓN AGENCIA ARAGONESA PARA LA INVESTIGACIÓN Y EL DESARROLLO (ARAID), FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDAInventors: Luis Alberto Anel Bernal, Raquel Ibañez Perez, Patricia Guerrero Ochoa, Luis Martinez Lostao, Blanca Conde Guerri, Ramón Hurtado Guerrero, Ana Laura Sanz Alcober, Rocio Navarro Ortiz
-
Patent number: 11859018Abstract: The present disclosure provides peptoid-based chelating ligands, corresponding cyclic peptoids, and methods of making thereof. Functional groups may be tailored for high metal binding affinity and selectivity. The side chains of a cyclic peptoid according to the present disclosure may be selected based on, for example, high affinity for actinide or other metal ions, selectivity for actinide or other metal ions, the ability to recover a metal once it is bound to the peptoid, and whether the overall peptoid should be hydrophobic or hydrophilic. Unlike siderophores, peptoid-based chelating ligands of the present disclosure are not readily hydrolyzed under physiological conditions. Therefore, peptoid-based chelating ligands may be, for example, used to treat actinide (e.g., iron and lead) poisoning in vivo. Moreover, peptoid-based chelating ligands of the present disclosure may be used for medical imaging, chelation therapy, drug delivery, and separation technologies, for example.Type: GrantFiled: January 14, 2022Date of Patent: January 2, 2024Assignee: TRIAD NATIONAL SECURITY, LLCInventors: Robert F. Williams, David Owen Baumann, John Cameron Gordon
-
Patent number: 11840559Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.Type: GrantFiled: November 30, 2021Date of Patent: December 12, 2023Assignee: i2o Therapeutics, Inc.Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
-
Patent number: 11795197Abstract: Described herein is a peptide, a multimodal peptide ligand imaging agent and methods for use in tumor targeting, tumor visualization, drug delivery and as an imaging ligand. The invention further provides for a theranostic peptide agent and methods for use in the treatment of cancer and/or inflammation in a subject.Type: GrantFiled: June 7, 2018Date of Patent: October 24, 2023Assignee: Cedars-Sinai Medical CenterInventors: Yong Yue, Yi Zhang
-
Patent number: 11771739Abstract: Disclosed are compositions and methods for treating microbial inflammation including its end-stage sepsis and conditions associated with the microbial inflammation such as thrombocytopenia and hypoglycogenemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial inflammation.Type: GrantFiled: June 18, 2018Date of Patent: October 3, 2023Assignees: Vanderbilt University, The United States As Represented By The Department Of Veterans AffairsInventors: Jack Jacek Hawiger, Jozef Zienkiewicz, Ruth Ann Veach, Yan Liu, Lukasz Wylezinski
-
Patent number: 11766414Abstract: Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.Type: GrantFiled: January 17, 2022Date of Patent: September 26, 2023Assignee: INDI MOLECULAR, INC.Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
-
Patent number: 11753449Abstract: Provided are a protein L-derived immunoglobulin binding protein having an increased alkali tolerance, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin ? chain binding activity.Type: GrantFiled: September 25, 2018Date of Patent: September 12, 2023Assignees: JSR CORPORATION, JSR Life Sciences Corporation, JSR Life Sciences, LLC, JSR Micro N.V.Inventors: Jun-ichi Yasuoka, Kiichi Yoshimura
-
Patent number: 11752196Abstract: The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1?) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1?) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1? that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF.Type: GrantFiled: September 21, 2020Date of Patent: September 12, 2023Inventors: Rajiv Jalan, Ugo Soffientini, Nigel Beaton, Gautam Mehta
-
Patent number: 11753445Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.Type: GrantFiled: April 11, 2022Date of Patent: September 12, 2023Assignee: COHBAR, INC.Inventors: Kenneth Cundy, Remi Magnan, Kent K. Grindstaff, Wendy Luo, Yongjin Yao, Liang Zeng Yan
-
Patent number: 11744875Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: GrantFiled: July 13, 2020Date of Patent: September 5, 2023Assignee: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Patent number: 11717556Abstract: The present invention relates to a stemness-suppressing composition comprising an OCT4 function-inhibiting peptide and, more particularly, to a composition comprising a peptide as an effective ingredient for suppressing the stemness of various stem cells such as general stem cells, cancer stem cells, and the like, wherein the peptide inhibits the function of OCT4 by inducing the phosphorylation of OCT4. OCT4 function-inhibiting peptides of the present invention are expected to find applications in various fields through the suppressive activity thereof against stemness of stem cells.Type: GrantFiled: March 5, 2019Date of Patent: August 8, 2023Assignee: NATIONAL CANCER CENTERInventors: Hyonchol Jang, Byung Il Lee, Hong-Duk Youn, Bomin Song
-
Patent number: 11712461Abstract: A polypeptide composition for treating atrial fibrillation includes a polypeptide that has a sequence: fADNYTRLRKQMAVKKYLNSILN-NH2 (SEQ ID NO: 1), From an N-terminus of the polypeptide, a first amino acid (f) is a D-Phe, a second amino acid is Ala, and a third amino acid is Asp; and the peptide is linear in a solution and forms an ?-helix structure after encountering a lipid bilayer.Type: GrantFiled: September 10, 2022Date of Patent: August 1, 2023Assignee: THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITYInventors: Yue Wu, Kaiyue Feng, Chaofeng Sun